Paper36596352
Artificial intelligence-based multi-omics analysis fuels cancer precision medicine.
He X and 4 others. Semin Cancer Biol, 2023. Cited by 317 papers, by iCite.
Cite this record
ConductScience Library. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. Papers, record 36596352. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36596352
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Artificial Intelligence | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Precision Medicine | |
| Multiomics | |
| Transcriptome |
Source PubMed
Cited by232
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 317 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42984500 | MR-supported candidate genes and pathway analysis between ischemic stroke and osteoporosis: an integrated multi-omics study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42984500 | PubMed |
| 42935868 | Neurovascular Retinomics for Noninvasive Profiling of Cancer Risk: A Prospective Cohort Study in the UK Biobank. | Ophthalmol Sci | 2026 | https://conductscience.org/library/papers/42935868 | PubMed |
| 42923287 | Research progress and clinical translation prospects of multiple urinary biomarkers in non-invasive diagnosis of urothelial carcinoma. | Front Oncol | 2026 | https://conductscience.org/library/papers/42923287 | PubMed |
| 42904056 | Cytomics-driven insights for investigating host-pathogen interactions. | Hlife | 2026 | https://conductscience.org/library/papers/42904056 | PubMed |
| 42898827 | Gut microbiota in esophageal cancer: mechanisms, clinical implications, and therapeutic potential. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42898827 | PubMed |
| 42890802 | Progress of metabolomics-centric multi-omics research in medicine. | IMetaOmics | 2026 | https://conductscience.org/library/papers/42890802 | PubMed |
| 42882898 | The Molecular Landscape of the Senescence-EMT Interplay: Deciphering Tumour Plasticity Through Molecular Signatures and Multi-Omic Profiling. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882898 | PubMed |
| 42824332 | Transition Toward Multimodal Integration in Cancer Therapy: Biological Rationales, Clinical Efficacy, and Pharmacological Challenges. | Cureus | 2026 | https://conductscience.org/library/papers/42824332 | PubMed |
| 42794948 | Biomimetic Nanocarriers for Glioblastoma Therapy: Translational Advances and Strategic Challenges. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42794948 | PubMed |
| 42782779 | Targeting Glycolytic Reprogramming in Gastric Cancer: Navigating the Translational Maze from Mechanism to Clinic. | Cells | 2026 | https://conductscience.org/library/papers/42782779 | PubMed |
| 42775263 | One patient with synchronous multiple primary colon cancers which is easy to miss: a case report. | Front Surg | 2026 | https://conductscience.org/library/papers/42775263 | PubMed |
| 42723078 | Multi-omics characterization of a GPRC5A+ epithelial subpopulation associated with malignant features in colorectal cancer. | J Transl Med | 2026 | https://conductscience.org/library/papers/42723078 | PubMed |
| 42699460 | Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42699460 | PubMed |
| 42656953 | Multi-omics-driven precision medicine. | Imeta | 2026 | https://conductscience.org/library/papers/42656953 | PubMed |
| 42652104 | AI-Guided Long Non-Coding RNA Target Discovery for Precision Medicine: Integrating GWAS, Multi-Omics, Experimental Validation, and RNA Therapeutics. | Biomedicines | 2026 | https://conductscience.org/library/papers/42652104 | PubMed |
| 42643518 | Editorial: AI-powered integrative multi-omics for precision cancer therapies. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42643518 | PubMed |
| 42619640 | Multi-omic analyses of the same sample using metabolomics, lipidomics, proteomics, phosphoproteomics, and glycoproteomics. | Chem Commun (Camb) | 2026 | https://conductscience.org/library/papers/42619640 | PubMed |
| 42583540 | Beyond the mutation: integrating radiogenomics, epigenetics, and immune signatures to overcome therapeutic resistance in CNS tumors: a narrative review. | Ann Med Surg (Lond) | 2026 | https://conductscience.org/library/papers/42583540 | PubMed |
| 42563687 | Multi‑omics insights into uveitis: From mechanisms to precision medicine (Review). | Int J Mol Med | 2026 | https://conductscience.org/library/papers/42563687 | PubMed |
| 42540689 | Beyond morphology: imaging the glioblastoma microenvironment in the era of quantitative neuro-oncology. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42540689 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36596352
GET https://conductscience.org/api/papers/v1/36596352/cited_by?page=2